Ranbaxy moves into vaccines with Biovel buy
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has acquired product rights and a manufacturing facility from the Indian vaccines and biotherapeutics firm, Biovel Lifesciences, for an undisclosed sum.